Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma, Cancer
RVMDRevolution Medicines IncCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for RMC-9805 (KRASG12D) in Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma, Cancer. The expected timing is based on the latest available company guidance and may change.
9/19/23- Dosed the first patient in Ph1/1b. 10/25/24- Data at AACR-NCI-EORTC. 4/27/25- Reported new clinical data at AACR '25. 03/17/26:- Present preliminary Ph1 safety/activity in KRAS G12D NSCLC at AACR Apr 19, 2026. 04/19/26:- Updated Ph1 RMC-9805-001 NSCLC data: ORR 52% (n=27); manageable safety. 06/23/26:- Began treating patients in Ph3 RASolute 305 zoldonrasib+chemo for 1L metastatic RAS G12D PDAC. 06/24/26:- Ph1/2 zoldonrasib combo results in 1L and 2L+ mPDAC presented July 2, 2026. 07/02/26:- ESMO GI: zoldonrasib+chemo ORR 82% mFFX, 61% GnP; supports ongoing Ph3 RASolute 305. Planned Ph3 RASolute 309 zoldonrasib+dara vs GnP.
Verification
Confirm timing and program details against the company announcement or filing.